Stock Track | PEIJIA-B Soars 7.75% Intraday on Strong Annual Results and Growth Prospects in TAVR and Neurointervention Segments

Stock Track

04/01

PEIJIA-B's stock soared 7.75% during intraday trading on Wednesday, reflecting strong investor sentiment.

The surge follows the company's release of its annual results, which showed revenue growth of 15.82% year-on-year to RMB 713 million. Revenue from TAVR-related products increased by 11.6% to RMB 290 million, while neurointervention products revenue rose 18.9% to RMB 423 million, with segment profit jumping 86.6% to RMB 97.2 million.

Institutional analysis highlights that the TAVR segment is expected to benefit from volume growth after national price negotiations and the commercialization of the regurgitation valve TaurusTrio in 2026. The neurointervention segment, with coils providing stable cash flow and DCwire micro-guidewires receiving FDA approval, is set to contribute overseas revenue. The company aims to achieve breakeven within the year, and with new products like TaurusNXT and GeminiOne TEER in registration, along with advancing clinical pipelines, a "Buy" rating has been maintained, driving the stock's upward movement.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/1135212271"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1135212271\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1135212271?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-01 15:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1135212271","market":"sg","top_or_hot":-1,"title":"Stock Track | PEIJIA-B Soars 7.75% Intraday on Strong Annual Results and Growth Prospects in TAVR and Neurointervention Segments","media":"Stock Track","content":"<p>PEIJIA-B's stock soared 7.75% during intraday trading on Wednesday, reflecting strong investor sentiment.</p><p>The surge follows the company's release of its annual results, which showed revenue growth of 15.82% year-on-year to RMB 713 million. Revenue from TAVR-related products increased by 11.6% to RMB 290 million, while neurointervention products revenue rose 18.9% to RMB 423 million, with segment profit jumping 86.6% to RMB 97.2 million.</p><p>Institutional analysis highlights that the TAVR segment is expected to benefit from volume growth after national price negotiations and the commercialization of the regurgitation valve TaurusTrio in 2026. The neurointervention segment, with coils providing stable cash flow and DCwire micro-guidewires receiving FDA approval, is set to contribute overseas revenue. The company aims to achieve breakeven within the year, and with new products like TaurusNXT and GeminiOne TEER in registration, along with advancing clinical pipelines, a \"Buy\" rating has been maintained, driving the stock's upward movement.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | PEIJIA-B Soars 7.75% Intraday on Strong Annual Results and Growth Prospects in TAVR and Neurointervention Segments</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | PEIJIA-B Soars 7.75% Intraday on Strong Annual Results and Growth Prospects in TAVR and Neurointervention Segments\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-04-01 15:36</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>PEIJIA-B's stock soared 7.75% during intraday trading on Wednesday, reflecting strong investor sentiment.</p><p>The surge follows the company's release of its annual results, which showed revenue growth of 15.82% year-on-year to RMB 713 million. Revenue from TAVR-related products increased by 11.6% to RMB 290 million, while neurointervention products revenue rose 18.9% to RMB 423 million, with segment profit jumping 86.6% to RMB 97.2 million.</p><p>Institutional analysis highlights that the TAVR segment is expected to benefit from volume growth after national price negotiations and the commercialization of the regurgitation valve TaurusTrio in 2026. The neurointervention segment, with coils providing stable cash flow and DCwire micro-guidewires receiving FDA approval, is set to contribute overseas revenue. The company aims to achieve breakeven within the year, and with new products like TaurusNXT and GeminiOne TEER in registration, along with advancing clinical pipelines, a \"Buy\" rating has been maintained, driving the stock's upward movement.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09996","symbol_name":"沛嘉医疗-B","start_time":0,"source_url":"","article_id":"1135212271","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1135212271","pubTimestamp":1775028966,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"PEIJIA-B's stock soared 7.75% during intraday trading on Wednesday, reflecting strong investor sentiment.The surge follows the company's release of its annual results, which showed revenue growth of...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"09996":"沛嘉医疗-B"},"translate_title":"个股赛道|沛嘉-B盘中大涨7.75%TAVR和神经介入板块强劲年度业绩和增长前景","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09996":1},"content_text":"PEIJIA-B's stock soared 7.75% during intraday trading on Wednesday, reflecting strong investor sentiment.The surge follows the company's release of its annual results, which showed revenue growth of 15.82% year-on-year to RMB 713 million. Revenue from TAVR-related products increased by 11.6% to RMB 290 million, while neurointervention products revenue rose 18.9% to RMB 423 million, with segment profit jumping 86.6% to RMB 97.2 million.Institutional analysis highlights that the TAVR segment is expected to benefit from volume growth after national price negotiations and the commercialization of the regurgitation valve TaurusTrio in 2026. The neurointervention segment, with coils providing stable cash flow and DCwire micro-guidewires receiving FDA approval, is set to contribute overseas revenue. The company aims to achieve breakeven within the year, and with new products like TaurusNXT and GeminiOne TEER in registration, along with advancing clinical pipelines, a \"Buy\" rating has been maintained, driving the stock's upward movement.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}